Cargando…

LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB

BACKGROUND: Targeted therapy aimed at modulating the RAS/RAF/MEK/ERK pathway is of increasing interest for patients with plexiform neurofibromas and low-grade gliomas. Trametinib is an FDA-approved MEK inhibitor that has little published pediatric experience to date. METHODS: A retrospective chart r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Tiffany, McMahon, Kathleen, Hemenway, Molly, Levy, Jean Mulcahy, Foreman, Nicholas, Dorris, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Low Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715454/ http://dx.doi.org/10.1093/neuonc/noaa222.409

Ejemplares similares

LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
por: Chan, Priya, et al.
Publicado: (2022)

LGG-16. TO BE PRECISE - KNOW YOUR TARGETS: INSTITUTIONAL EXPERIENCE WITH TUMOR TARGETED THERAPY FOR RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA AND PLEXIFORM NEUROFIBROMA
por: Silverman, Mackenzie, et al.
Publicado: (2021)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS
por: Hanzlik, Emily, et al.
Publicado: (2021)

LGG-12. TRAMETINIB FOR PEDIATRIC LOW GRADE GLIOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Barbour, Mustafa, et al.
Publicado: (2020)

LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01
por: Perreault, Sébastien, et al.
Publicado: (2020)

LGG-30. TRAMETINIB-ASSOCIATED HYPONATREMIA IN A CHILD WITH LOW GRADE GLIOMA IS NOT SEEN FOLLOWING TREATMENT WITH ALTERNATIVE MEK INHIBITOR
por: Lazow, Margot A, et al.
Publicado: (2020)

LGG-12. SAFETY AND EFFICACY OF DUAL THERAPY WITH DABRAFENIB AND TRAMETINIB IN AN INFANT WITH BRAF V600E MUTANT INOPERABLE LOW GRADE GLIOMA
por: Green, Sage, et al.
Publicado: (2021)

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS
por: Grob, Sydney, et al.
Publicado: (2020)

LGG-55. Autophagy sensitizes CNS tumors to targeted therapy by lowering their apoptotic threshold
por: Crespo, Michele, et al.
Publicado: (2022)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION
por: Uchida, Hiroyuki, et al.
Publicado: (2020)

LGG-57. SIGNALLING MECHANISMS IN PAEDIATRIC LOW-GRADE GLIOMA
por: Patel, Ankit, et al.
Publicado: (2020)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-46. MOLECULAR CHARACTERIZATION OF HEMISPHERIC LOW-GRADE GLIOMAS IN CHILDREN
por: Mišove, Adéla, et al.
Publicado: (2020)

LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS
por: Bennett, Julie, et al.
Publicado: (2020)

LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults
por: Bennett, Julie, et al.
Publicado: (2022)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-44. PROGNOSTIC SIGNIFICANCE OF IMAGING CHARACTERISTICS IN PEDIATRIC LOW GRADE GLIOMAS
por: Baig, Muhammad, et al.
Publicado: (2020)

LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA
por: Sirachainan, Nongnuch, et al.
Publicado: (2020)

LGG-10. AN UNUSUAL PRESENTATION OF BILATERAL OPTIC NERVE GLIOMA IN CROUZON SYNDROME
por: Na, Brian, et al.
Publicado: (2021)

LGG-02. PEDIATRIC LOW-GRADE GLIOMA RISK STRATIFICATION IN THE MOLECULAR ERA
por: Hata, Jessica, et al.
Publicado: (2021)

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas
por: Lindsay, Holly, et al.
Publicado: (2022)

LGG-59. Identifying hidden drivers of low-grade glioma tumor growth
por: Misek, Sean, et al.
Publicado: (2022)

LGG-20. Defining subgroups in low grade gliomas by their immune and stromal microenvironment
por: Körner, Meik, et al.
Publicado: (2022)

LGG-61. Cerebrospinal fluid as a source for liquid biopsy in pediatric gliomas
por: Nobre, Liana, et al.
Publicado: (2022)

LGG-36. Analysis of BRAF-related mutations in pediatric low-grade glioma
por: Li, Shaoqun, et al.
Publicado: (2022)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

LGG-14. PRESENTATION CHARACTERISTICS AND TREATMENT OUTCOMES FOR PEDIATRIC OPTIC PATHWAY GLIOMAS IN QATAR
por: Maaz, Ata, et al.
Publicado: (2021)

LGG-22. EVALUATION OF IMMUNE AND GENOMIC CHARACTERISTICS IN PEDIATRIC OPTIC NERVE GLIOMA (ONG)
por: Campbell, Ashley A, et al.
Publicado: (2020)

LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
por: Verrico, Antonio, et al.
Publicado: (2022)

LGG-54. Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia
por: Chatterjee, Jit, et al.
Publicado: (2022)

LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1
por: Fisher, Michael, et al.
Publicado: (2021)

LGG-15. COMPREHENSIVE ANALYSIS OF MYB/MYB1-ALTERED GLIOMAS: A MULTI-INSTITUTIONAL EXPERIENCE OF 33 GLIOMAS
por: Moreira, Daniel, et al.
Publicado: (2021)

LGG-52. BINIMETINIB IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA NOT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1: INITIAL RESULTS FROM A MULTI-INSTITUTIONAL PHASE II STUDY
por: Robison, Nathan, et al.
Publicado: (2020)

LGG-01. CLINICAL MANAGEMENT AND GENOMIC PROFILING OF PEDIATRIC LOW-GRADE GLIOMAS IN SAUDI ARABIA
por: Mobark, Nahla A, et al.
Publicado: (2020)

LGG-01. NF1 MUTATION DRIVES NEURONAL ACTIVITY-DEPENDENT OPTIC GLIOMA INITIATION
por: Pan, Yuan, et al.
Publicado: (2021)

LGG-37. Long-term Outcome, Visual Morbidity and Prognostic Factors in Infants and Young Children with Optic Pathway Glioma from the Great Ormond Street Hospital (GOSH) LGG - Cohort
por: Picariello, Stefania, et al.
Publicado: (2022)

LGG-04. A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (pLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Fangusaro, Jason, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_79e6p41pc9du9v7861tppihg3k